Morag Peberdy has broad experience in all areas of intellectual property, where she advises on both contentious and non-contentious issues. Her wide-ranging expertise includes patents, trademarks, designs, copyright, database rights and confidential information, and covers drafting intellectual property agreements and infringement and contractual disputes. Her particular focuses have been on patent work in the life science sector, and in advising branded goods companies.
The consultation period for the draft proposed Rules of Procedure of the Unified Patents Court (“Rules”) closes on 1 October 2013. Any life science business with European operations will, sooner or later, find itself before the Unified Patents Court once it becomes operational, either as a claimant or defendant. The consequences of that litigation will … Continue Reading
By Morag Peberdy and Christina Helden Life sciences companies are already contemplating changing their patent strategies in anticipation of the EU’s Unitary Patent. However, the timeline for the EU Unitary Patent has been delayed. When the legislative package was agreed last December, many speculated that the 1 January 2014 date for the implementation of the … Continue Reading
This post originally appeared on our sister blog, InsideTechMedia. After more than 40 years of discussions, the European Parliament today voted in favour of the “EU patent package,” hot on the heels of the European Council’s approval yesterday. The EU patent package will create a Unitary EU Patent i.e. a uniform patent which will have equal effect and will … Continue Reading
Article originally published in the Briefing paper for the BioIndustry Association on October 9, 2012 Background: This note provides an introduction to trade marks and designs, from a European perspective. It aims to explain the relevance of trade marks and designs to bioscience companies. It has been prepared by Morag Peberdy of Covington & Burling LLP, … Continue Reading
Article originally published in PLC Life Sciences Handbook 2012 M&A in the life sciences sector has remained robust, driven by factors such as: The need to replenish shrinking product pipelines. The need to maintain revenues as patents on top-selling products expire. The strategic diversification of business lines. Expansion into emerging markets. … Continue Reading
Article originally published in PLC Life Sciences Handbook 2009/2010 Many life science companies rely on their employees’ inventiveness to fuel their research and development (R&D) efforts and generate patents. The most successful inventions can generate billions of euros of sales annually. In some circumstances, the employees who created the patentable inventions may be entitled to … Continue Reading